

February 03, 2026

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
Scrip Code – 526783

Dear Sir/ Madam,

Subject: Outcome of Board Meeting

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, we wish to inform you that the Board of Directors at their meeting held today, i.e., Tuesday, February 03, 2026, inter-alia approved the following:

1. Unaudited Financial Results:

Unaudited financial results along with the limited review report from the statutory auditors for the quarter and nine months ended December 31, 2025.

Further, the financial results will be published in the newspaper in compliance with Regulation 47 of SEBI (LODR) Regulations, 2015. The financial results will also be available on the website of the Company – www.dragarwal.com. A copy of the extracts of the results to be published is enclosed.

2. Shifting of registered office of the Company within local limits of the city.

To facilitate better administrative convenience and infrastructure requirements, the Registered Office of the Company is shifted from 3rd Floor, Buhari Towers, No.4, Moores Road, Off. Greams Road, Chennai, Tamil Nadu- 600 006 to **6th Floor, 1st Main Road, Austin Nagar, Alwarpet, Chennai, Tamil Nadu 600 018** with effect from February 05, 2026.

The shifting of registered office is within the local limits of the city of Chennai.

The meeting commenced at 02:00 p.m. and concluded at 02:55 p.m.

Yours truly

For **Dr. Agarwal's Eye Hospital Limited**

Meenakshi Jayaraman
Company Secretary & Compliance Officer

Dr. Agarwal's Eye Hospital Limited

Regd. & Corporate Office

3rd Floor, Buhari Towers, No.4 Moores Road, Off Greams Road, Near Asan Memorial School, Chennai – 600 006.

Tel: +91 44 4378 7777 | +91 44 4378 7778 | CIN: L85110TN1994PLC027366 | GST No: 33AAACD2373G1Z2

Email: info@dragarwal.com | Website: www.dragarwal.com

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Dr. Agarwal's Eye Hospital Limited**

1. We have reviewed the accompanying statement of Unaudited Ind AS Financial Results of Dr. Agarwal's Eye Hospital Limited (the "Company") for the quarter ended December 31, 2025 and year to date from April 01, 2025 to December 31, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

5. The comparative unaudited Ind AS financial information of the Company for the corresponding quarter and year to date from April 01, 2024 to December 31, 2024, included in these unaudited Ind AS financial results, were reviewed by the predecessor auditor who expressed an unmodified conclusion on those unaudited Ind AS financial results on February 14, 2025. The audited Ind AS financial statements of the Company for the year ended March 31, 2025, were audited by predecessor auditor who expressed an unmodified opinion on those financial statements on May 28, 2025.

For S.R. Batliboi & Associates LLP
Chartered Accountants
ICAI Firm registration number: 1011049W/E300004

Aravind K.
per Aravind K
Partner
Membership No.: 221268
Chennai, Tamil Nadu
February 03, 2026
UDIN: 26221268YPNUYX3216



(Amounts in INR Crores except EPS)

Statement of Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2025.

S.No.	Particulars	Quarter Ended		Nine months ended		Year Ended 31-Mar-25 Audited (Refer Note 3)
		31-Dec-25 Unaudited	30-Sep-25 Unaudited	31-Dec-24 Unaudited (Refer Note 3)	31-Dec-25 Unaudited	
1	Income					
	(a) Revenue from Operations	116.22	117.72	95.11	350.86	297.32
	(b) Other Income	2.77	0.88	2.31	4.25	4.99
	Total Income	118.99	118.40	97.42	355.11	302.31
						402.24
2	Expenses					
	(a) Purchase of Stock-in-Trade	11.98	11.85	10.89	35.70	34.08
	(b) Changes in Inventories of Stock-in-Trade - (Increase) / Decrease	(0.26)	0.07	(0.68)	0.18	(2.77)
	(c) Consumption of Surgical lens including other consumables	13.74	12.87	11.88	40.80	36.70
	(d) Consultancy Charges for Doctors (Net)	15.41	14.60	11.66	45.40	38.43
	(e) Employee Benefit Expense	24.10	21.44	20.90	87.72	58.37
	(f) Finance Costs	2.03	3.73	3.85	9.92	10.55
	(g) Depreciation and Amortisation Expense	11.66	11.31	10.02	33.55	29.25
	(h) Other Expenses	16.88	16.71	14.86	49.87	44.60
	Total Expenses	95.54	92.88	83.36	282.75	250.21
						331.54
3	Profit before tax (1-2)	23.45	25.72	14.06	72.36	52.10
	Tax Expense					
	- Current Tax (including tax pertaining to earlier years)	5.80	6.86	3.85	18.58	13.79
	- Deferred Tax (Net)	0.37	(0.46)	(0.19)	(0.08)	(0.35)
4	Total tax expenses	6.17	6.40	3.56	18.50	13.44
5	Net Profit after tax for the period (3-4)	17.28	19.32	10.40	53.86	38.66
6	Other Comprehensive Income					
	(a) Items that will not be reclassified to the Statement of Profit and Loss					
	- Remeasurement gain / (loss) on defined benefit obligation	(0.28)	0.06	(0.12)	(0.16)	(0.37)
	- Tax on items that will not be reclassified to the Statement of Profit and Loss	0.08	(0.02)	0.03	0.04	0.09
	Total Other Comprehensive Income (net of tax)	(0.20)	0.04	(0.09)	(0.12)	(0.28)
7	Total Comprehensive Income (5+6)	17.08	19.36	10.31	53.74	38.38
8	Paid-up equity share capital (Face value INR 10/- each)	4.83	4.83	4.70	4.83	4.70
9	Reserves (Other Equity)					204.91
10	Earnings Per Equity Share (EPS) (Face value of INR 10/- each)					
	(a) Basic	35.76	41.04	22.13	113.46	82.26
	(b) Diluted	35.76	41.04	22.13	113.46	82.26
	Additional Information:					
	Earnings before finance cost, depreciation, amortisation and tax (EBITDA) (Refer Foot Note)	37.14	40.76	27.93	115.83	91.90
						123.59

See accompanying notes to the financial results

Foot note:

(i) The company has presented information on EBITDA additionally as a part of the statement of financial results as defined above.
 (ii) EBITDA= Profit before tax + Depreciation and Amortization Expense + Finance Costs

By order of the Board

Dr. Amar Agarwal
 Chairman & Managing
 Director
 DIN No. 00435684

Place : Chennai

Date: February 03, 2026



Dr. Agarwal's Eye Hospital Limited

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006
Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com

Dr Agarwals
Eye Hospital

Statement of Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2025.

Notes:

- 1 These unaudited financial results have been prepared in accordance with the recognition and measurement principles provided in Indian Accounting Standard (Ind AS) 34 on 'Interim Financial Reporting', the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI) under SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.
- 2 The above unaudited financial results have been reviewed by the Audit Committee and the same has been approved and taken on record by the Board of Directors in their respective meetings held on February 03, 2026. The above unaudited financial results for the quarter and nine months ended December 31, 2025, has also been subjected to limited review by the Statutory Auditors of the Company.
- 3 The comparative financial results for the corresponding quarter and nine months ended December 31, 2024, and year ended March 31, 2025, were reviewed / audited (as applicable) by the predecessor Statutory Auditors of the Company.
- 4 The Company operates in a single segment i.e., "Eye Care related sales and services" and does not have any additional disclosures to be made under Ind AS 108 – Operating Segments.
- 5 The Board of Directors of the Company, at its meeting held on August 27, 2025, approved the proposed scheme of amalgamation ("the Scheme") with its Holding Company, Dr. Agarwal's Health Care Limited ("AHCL"). The Scheme is subject to the requisite approvals from respective shareholders and the applicable regulatory approvals.
- 6 The Board of Directors of the Company, at its meeting held on August 27, 2025, approved the issuance of 1,32,827 equity shares of the Company having face value of Rs.10 each at a price of Rs.5,270 per share by way of Preferential issue amounting to Rs. 70 crores to Dr. Agarwal's Health Care Limited. This was approved by the shareholders in its Annual General Meeting held on September 24, 2025 and the relevant shares were allotted on September 26, 2025. The Company has received the listing and trading approvals from the stock exchange on October 16, 2025 and October 28, 2025, respectively. The Company has utilised Rs. 13 crores of the proceeds of preferential allotment as per the terms of objects which were approved by the shareholders and the balance unutilised portion as on December 31, 2025 have been temporarily invested in debt mutual funds by the Company.
- 7 On November 21, 2025, the Government of India has notified the four labour codes, consolidating 29 existing labour legislations into a unified framework as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code 2020 (collectively referred to as the "New Labour Codes"). These legislative changes have revised the definition of wages for the purpose of computation of employee benefits and expanded the scope and eligibility of certain employee related social security benefits. The Government is also in the process of issuing related rules to the New Labour Codes.

Based on Company's assessment, information currently available and consistent with the FAQs on key accounting implications arising from the New Labour Codes issued by the Institute of Chartered Accountants of India, the provisions currently in force do not have a material impact on the financial results of the Company. The Government is in the process of notifying related rules to the New Labour Codes and impact of these will be evaluated and the financial impact, if any, will be accounted for in accordance with applicable accounting standards in the period in which they are notified.

- 8 The Company does not have any subsidiary / associate / joint venture entity for the quarter and nine months ended December 31, 2025.



By order of the Board


Dr. Amar Agarwal
Chairman & Managing Director
DIN No. 00435684

Place : Chennai
Date : February 03, 2026



Dr. Agarwal's Eye Hospital Limited
CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No. 4, Moores Road, Off Greams Road, Chennai - 600 006
Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com

Dr Agarwals
Eye Hospital

(Amounts in INR Crores except EPS)

Statement of Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2025.

Particulars	Quarter Ended			Nine months ended		Year ended
	31-Dec-25 (Unaudited)	30-Sep-25 (Unaudited)	31-Dec-24 Unaudited (Refer Note 3)	31-Dec-25 (Unaudited)	31-Dec-24 Unaudited (Refer Note 3)	31-Mar-25 Audited (Refer Note 3)
Revenue from Operations	116.22	117.72	95.11	350.86	297.32	397.15
Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	23.45	25.72	14.06	72.36	52.10	70.70
Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	23.45	25.72	14.06	72.36	52.10	70.70
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	17.28	19.32	10.40	53.86	38.66	54.65
Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	17.08	19.36	10.31	53.74	38.38	54.81
Paid-up Equity Share Capital (Face Value of INR 10/- each)	4.83	4.83	4.70	4.83	4.70	4.70
Reserves (Other Equity)	-	-	-	-	-	204.91
Earnings Per Share (for continuing and discontinued operations) (Face Value of INR 10/- each):						
(a) Basic	35.76	41.04	22.13	113.46	82.26	116.28
(b) Diluted	35.76	41.04	22.13	113.46	82.26	116.28
	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	-

Notes:

- 1) The above is an extract of the detailed format of Quarterly Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results is available on the Stock Exchange website (www.bseindia.com) and on the Company's website (www.dragarwal.com).
- 2) The above unaudited financial results have been reviewed by the Audit Committee and the same has been approved and taken on record by the Board of Directors at their respective meetings held on February 03, 2026. The above results for the quarter and nine months ended December 31, 2025 has also been subjected to limited review by the Statutory Auditors of the Company.
- 3) The comparative financial results for the corresponding quarter and nine months ended December 31, 2024, and year ended March 31, 2025, were reviewed / audited (as applicable) by the predecessor Statutory Auditors of the Company.

Place : Chennai
Date : February 03, 2026



Dr. Amar Agarwal
Chairman & Managing Director
DIN No. 00435684